First Published: 26th March 2025
Cumulus Neuroscience will present data at AD/PD 2025 in Vienna, Austria.
The following posters were accepted by the AD/PD Scientific Program Committee:
- Neuropsychological phenotyping of Alzheimer's dementia at home, using the Cumulus NeuLogiq® Platform with plasma biomarkers
- Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations
“We have further validated the longitudinal performance of these cognitive tasks against the ADAS-Cog benchmark, examined the relationship of the digital test endpoints to pTau217 status, and evaluated the feasibility of NeuLogiq with patients living with FTD and ALS.”
Brian Murphy, Ph.D.
CSO, Cumulus Neuroscience
“At AD/PD 2024, our team presented a poster which featured validation data for two novel cognitive tasks from our NeuLogiq Platform which strongly differentiated dementia status with equivalent or greater sensitivity than the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog),” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Additionally, these data confirmed that NeuLogiq is patient-friendly and can be used autonomously to capture high quality data at home, making them suitable for use in clinical trials. We have further validated the longitudinal performance of these cognitive tasks against the ADAS-Cog benchmark, examined the relationship of the digital test endpoints to pTau217 status, and evaluated the feasibility of NeuLogiq with patients living with FTD and ALS. We look forward to sharing these new data at AD/PD 2025.”
Cumulus poster presentation details are as follows:
Poster 1- Title: Neuropsychological phenotyping of Alzheimer's dementia at home, using the Cumulus NeuLogiq Platform with plasma biomarkers
- Poster Number: SHIFT 02-328
- Theme A: B-Amyloid Diseases / A04.I. Imaging, Biomarkers, Diagnostics: Cognitive, Psychometric & Behavioral Tests, Digital Endpoints, Remote Testing
- Title: Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations
- Poster Number: SHIFT 02-658
- Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D03. Imaging, Biomarkers, Diagnostics
Friday, April 4, 2025:
- 10:40 - 11:10 AM
- 12:50 - 13:50 PM
- 15:50 - 16:20 PM
- 10:40 - 11:10 AM
- 12:50 - 13:50 PM
- 15:50 - 16:20 PM
Cumulus continues to advance NeuLogiq, an integrated AI-based, multi-domain digital biomarker platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com.
NEULOGIQ is a registered UK Trademark under No. UK00004055380.